Pheno Therapeutics
A biotechnology company focused on the discovery and development of small molecule therapeutics that promote remyelination for the treatment of neurological diseases such as multiple sclerosis.
The UK-based company's differentiated small molecule drug discovery platform was built to deliver a new class of transformative regenerative and neuroprotective therapeutics.
In Jnauray 2023, Pheno announced a licensing deal with Belgium’s largest drugmaker UCB. The exclusive worldwide license agreement will give the UCB access to a pre-clinical-stage program of novel small molecules in return for an undisclosed upfront payment. Pheno will gain the rights to develop, manufacture and commercialize the assets.
Latest Pheno Therapeutics News & Features
11 January 2023
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze